RARE
Ultragenyx
15.50$
+1.2%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +29.9% | -14.6% | +35.1% | -5.1% | +18.2% | -15.5% | +19.5% | -3.9% | +29.4% | -34.3% | +57.4% | – | |
| – | +9.7% | +45.5% | +21.4% | -1.2% | -19.6% | +69.7% | -19.7% | +21.7% | +3.6% | +3.4% | +13.3% | – | |
| – | +32.5% | -20.8% | +37.7% | -5.8% | +24.9% | -25.2% | +29.7% | -8.1% | +34.9% | -40.4% | +69.8% | – | |
| – | +2.1% | +11.2% | -9.5% | +5.3% | +10.4% | -11.7% | -0.6% | +31.2% | -6.1% | -7.9% | -10.7% | – | |
| – | +2.6% | +1.7% | +3.1% | -0.3% | +2.7% | +6.4% | -1.3% | 0.0% | +1.5% | +0.1% | +0.0% | – | |
| – | +2.3% | +8.1% | -5.7% | +3.5% | +7.9% | -6.2% | -0.9% | +20.5% | -3.6% | -5.8% | -7.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -1.9% | -8.5% | +0.7% | -1.6% | -1.2% | -7.6% | -2.1% | +0.8% | +34.3% | +10.5% | +4.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -669.5% | – | +88.6% | -64.7% | -106.3% | – | -27.7% | -7.8% | +14.5% | +0.0% | +0.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.